-
Oral Dis: Measuring LDH in saliva can be a useful method for screening for oral cancer and potentially malignant diseases of the oral cavity
Time of Update: 2022-01-23
A study published in Oral Dis evaluated whether salivary lactate dehydrogenase (LDH) levels were increased in patients with oral cancer (OC) or underlying oral malignancy (OPMD) compared with healthy controls (CG) .
-
The fertility hope of gynecological cancer patients, you need to know these
Time of Update: 2022-01-23
In recent years, with the younger age of onset of malignant tumors and the general postponement of the reproductive age of women, fertility protection has become a difficult problem that often needs to be weighed and solved when clinically formulating treatment plans for cancer patients .
-
up to date!
Time of Update: 2022-01-23
On January 12, CA: A Cancer Journal for Clinicians, a journal of the American Cancer Society, released a report: Cancer Statistics 2022, which projected the number of new cancer cases and deaths in the United States this year .
-
J Clin Oncol: The KEYNOTE-158 study shows that pembrolizumab (pembrolizumab) has a significant effect in the treatment of MSI-H/dMMR endometrial cancer patients
Time of Update: 2022-01-23
Secondary endpoints included duration of response, progression-free survival, overall survival, and safety .
immunity TRAETRAEIn conclusion, the KEYNOTE-158 study shows that Pembrolizumab (pembrolizumab) is effective and safe and controllable in the treatment of MSI-H/dMMR endometrial cancer patients .
-
Radiology: This MRI technology makes prostate cancer nowhere to hide!
Time of Update: 2022-01-23
A study published in the journal Radiology provides a powerful technique for accurate preoperative diagnosis and staging of prostate cancer by comparing tissue composition measured using preoperative HM MRI with quantitative histological analysis after prostatectomy.
-
European Radiology: Breast cancer subtype analysis without surgery - quantitative assessment by DCE and DWI MRI
Time of Update: 2022-01-23
Studies have quantified the kinetic heterogeneity of breast cancer and calculated differences in apparent diffusion coefficients (ADCs) using dynamic contrast-enhanced (DCE) MRI and diffusion-weighted imaging (DWI) in combination with conventional clinical The protocol assessed intratumoral heterogeneity .
-
Front Oncol: A retrospective study comparing nab-paclitaxel and docetaxel as neoadjuvant therapy in patients with HER2- breast cancer
Time of Update: 2022-01-23
statistics Efficacy assessmentEfficacy assessmentAfter subgroup analysis, triple-negative breast cancer (TNBC) patients had a higher pCR rate in the nab-paclitaxel group than in the docetaxel group (62.
After subgroup analysis, triple-negative breast cancer (TNBC) patients had a higher pCR rate in the nab-paclitaxel group than in the docetaxel group (62.
-
JAMA Oncology: Sedentary life greatly increases the risk of death in cancer patients
Time of Update: 2022-01-23
from Washington University School of Medicine published a research paper titled: Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer Survivors in the journal JAMA Oncology .
-
Thorac Cancer: Maintenance therapy with apatinib after standard first-line chemotherapy in patients with extensive-stage small cell lung cancer (ED-SCLC) further prolongs survival
Time of Update: 2022-01-23
hypertension Adverse reactionsAdverse reactionsIn conclusion, studies have shown that maintenance therapy with apatinib after standard first-line chemotherapy in patients with extensive-stage small cell lung cancer (ED-SCLC) can further prolong survival, but the number of specimens is small, and further exploration is needed in the future .
-
Clin Cancer Res: The efficacy of mTOR inhibitor sapanisertib combined with fulvestrant in the treatment of postmenopausal women with advanced breast cancer with ER+/HER2- after progression on aromatase inhibitor
Time of Update: 2022-01-23
Postmenopausal women with estrogen receptor-positive (ER+)/HER2 advanced or metastatic breast cancer that progressed during or after aromatase inhibitor therapy were randomized to receive fulvestrant 500 mg alone, fulvestrant plus sapanisertib 4 mg QD, or Fulvestrant plus sapanisertib 30 mg QW until disease progression, unacceptable toxicity, withdrawal consent, or study termination .
-
Nature Cancer: Let cancer cells "stay awake"!
Time of Update: 2022-01-23
Comparison of collagen types between T-HEp3 (proliferating tumor) and D-HEp3 (dormant tumor) (Image source: Nature Cancer)Next, the researchers used a human-mouse xenograft system to further determine the relative contribution of tumor cells (human protein sequences) and stromal cells (mouse protein sequences) to matrix body production .
https://doi.
-
Front Oncol: Cisplatin combined with irinotecan for first-line treatment of metastatic or unresectable thymic carcinoma
Time of Update: 2022-01-23
PFS and OSPFS and OSFifteen patients received S-1 as a second- or later-line regimen, with an ORR of 33% and a median progression-free survival of 8.
Fifteen patients received S-1 as a second- or later-line regimen, with an ORR of 33% and a median progression-free survival of 8.
-
J Clin Oncol: Over 10-year OS results from the randomized FinXX study suggest that adding capecitabine to adjuvant chemotherapy improves outcomes in patients with early breast cancer
Time of Update: 2022-01-23
OS subgroup analysis OS subgroup analysisIn conclusion, the FinXX study showed that the addition of capecitabine to adjuvant chemotherapy could improve the prognosis of patients with early breast cancer .
In conclusion, the FinXX study showed that the addition of capecitabine to adjuvant chemotherapy could improve the prognosis of patients with early breast cancer .
-
Clin Cancer Res: Adavosertib combined with various chemotherapy drugs in the treatment of primary platinum-resistant ovarian, fallopian tube, and peritoneal cancers
Time of Update: 2022-01-23
The cohort with the highest response rate was the carboplatin plus Adavosertib group The longest duration of response was in the paclitaxel cohort (12.
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study .
-
Clin Cancer Res: MONALEESA-7 study update results show that Ribociclib combined with endocrine therapy consistently improves the prognosis of patients with HR+/HER2- advanced breast cancer compared with endocrine monotherapy
Time of Update: 2022-01-23
Overall, 177 (53%) and 221 (66%) patients receiving ribociclib and placebo, respectively, experienced disease progression or died of any cause on subsequent therapy .
The updated results of the MONALEESA-7 study showed that Ribociclib combined with endocrine therapy continued to improve the prognosis of patients with HR+/HER2- advanced breast cancer compared with endocrine monotherapy .
-
Hong Kong study: Only low doses can reduce the risk of lung cancer and death by 1/4 in COPD patients!
Time of Update: 2022-01-23
A recent cohort study showed that use of low-dose aspirin for more than 5 years was associated with a modest reduction in lung cancer risk .
After multivariate adjustment, aspirin users had a 25% lower risk of lung cancer than nonusers (Table 2, SHR = 0.
-
Eur J Epidemiol: Esophageal lesions strongly associated with increased risk of esophageal cancer
Time of Update: 2022-01-23
2)Taken together, this study demonstrates that patients with esophageal inflammation and other metaplastic abnormalities other than Barrett's esophagus also have a higher risk of EAC and GCA compared with the general population .
-
J Thorac Oncol: The third-generation EGFR-TKI lazertinib has significant curative effect and is safe and controllable in the treatment of T790m mutant NSCLC patients
Time of Update: 2022-01-23
In patients with advanced epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer ( NSCLC ), acquired EGFR T790M mutation is responsible for the development of resistance after treatment with first- or second-generation tyrosine kinase inhibitors (TKIs) The most common cause of sex .
-
BJU Int: a population-based randomized trial of clinically significant prostate cancer screening
Time of Update: 2022-01-23
Recently, researchers from Finland published an article in BJU Int evaluating the feasibility of a population-based screening test using prostate-specific antigen (PSA), kallikrein panel and multiparametric magnetic resonance imaging (MRI).
-
NEJM: The third-generation immune checkpoint comes into play: LAG-3+PD-1, doubles progression-free survival in advanced cancer
Time of Update: 2022-01-23
In this phase II/III double-blind randomized controlled clinical trial, a total of 714 patients with previously untreated advanced melanoma were randomized 1:1 to receive either Relatlimab + Nivolumab combination therapy or Nivolumab monotherapy .
